VERA in the 13F filings
Vera Therapeutics Inc · CUSIP 92337R101
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 26
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 3 listed it in both
- Shares listed
- 13,647,900
- combined, among listed positions
- Reported value
- $563m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 18 buyers (opened or added shares) and 10 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -1,882,659.
Managers listing VERA in Q1 2026
26 of 26 holders
Largest increases and reductions, by shares
Increases
- Balyasny Asset Management LLCexisting position · 419,570 shares now+365,243
- Renaissance Technologies LLCexisting position · 457,300 shares now+263,900
- ExodusPoint Capital Management LPexisting position · 317,351 shares now+244,610
- Hudson Bay Capital Management LPnew position · 192,439 shares now+192,439
- Freestone Grove Partners LPnew position · 146,097 shares now+146,097
Reductions
- T. Rowe Price Associates Incexisting position · 4,574,030 shares now-887,946
- Point72 Asset Management LPexisting position · 1,210,725 shares now-527,660
- Citadel Advisors LLCexisting position · 429,761 shares now-347,727
- Fidelity (FMR LLC)existing position · 2,676,422 shares now-209,431
- Susquehanna International Group LLPexisting position · 121,020 shares now-55,664
New positions and exits
New (6)
Exited (3)
- Holocene Advisors LPwas $66m
- Schonfeld Strategic Advisors LLCwas $1.6m
- Brevan Howard Capital Management LPwas $568k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2022 | 1 | $3.6m | n.a. | n.a. |
| Q4 2022 | 3 | $7.8m | n.a. | n.a. |
| Q1 2023 | 1 | $14m | n.a. | n.a. |
| Q2 2023 | 2 | $28m | n.a. | n.a. |
| Q3 2023 | 1 | $35m | n.a. | n.a. |
| Q4 2023 | 1 | $39m | 0 | 1 |
| Q1 2024 | 6 | $185m | 5 | 1 |
| Q2 2024 | 5 | $257m | 4 | 1 |
| Q3 2024 | 6 | $346m | 5 | 1 |
| Q4 2024 | 4 | $351m | 3 | 1 |
| Q1 2025 | 2 | $77m | 1 | 1 |
| Q2 2025 | 2 | $68m | 2 | 0 |
| Q3 2025 | 3 | $71m | 2 | 1 |
| Q4 2025 | 4 | $481m | 17 | 9 |
| Q1 2026 | 6 | $299m | 18 | 10 |
| Q2 2026 | 1 | $43m | 8 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
VERA and LLY →VERA and JNJ →VERA and VRTX →Choose a stock to compare with VERA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own VERA, latest filings →Back to the 13F Explorer →